Session » Systemic Sclerosis & Related Disorders – Clinical Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2462

A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2449

Acid Reflux Triggers Type I Interferon and Persistent Epithelial-mesenchymal Transition in Esophageal Epithelial Cells. a Novel Microenvironment Contribution to the Pathogenesis of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2454

Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020

10:30AM-12:30PM: Abstract Number: 2472

Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?

10:30AM-12:30PM: Abstract Number: 2471

Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2468

Audio-Guided Imagery Positively Impacted Patients with Raynaud’s Phenomenon Associated Connective Tissue Disease

10:30AM-12:30PM: Abstract Number: 2442

Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study

10:30AM-12:30PM: Abstract Number: 2448

Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function

10:30AM-12:30PM: Abstract Number: 2473

Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study

10:30AM-12:30PM: Abstract Number: 2450

Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients

10:30AM-12:30PM: Abstract Number: 2445

Effects of Aminaphtone on TGF-beta1 Serum Concentration as Concomitant Treatment to Standard Therapy in Systemic Sclerosis Patients: A Pilot Study

10:30AM-12:30PM: Abstract Number: 2467

Elderly Systemic Sclerosis. Clinical Presentation and Outcome

10:30AM-12:30PM: Abstract Number: 2447

Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort

10:30AM-12:30PM: Abstract Number: 2453

Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study

10:30AM-12:30PM: Abstract Number: 2456

High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2474

High-throughput Screening Identifies Specific Molecular Markers for ILD in Patients with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 2455

Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)

10:30AM-12:30PM: Abstract Number: 2463

Interstitial Lung Disease in Very Early Systemic Sclerosis – a Clinical and Radiological Characterization

10:30AM-12:30PM: Abstract Number: 2441

Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis

10:30AM-12:30PM: Abstract Number: 2469

Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis

10:30AM-12:30PM: Abstract Number: 2452

Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study

10:30AM-12:30PM: Abstract Number: 2446

Nailfold Videocapillaroscopy Findings in Patients with Limited Cutaneous versus Diffuse Cutaneous Systemic Sclerosis: The First Detailed Retrospective Study

10:30AM-12:30PM: Abstract Number: 2444

Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups

10:30AM-12:30PM: Abstract Number: 2457

Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study

10:30AM-12:30PM: Abstract Number: 2461

Prevalence and Impact of Peripheral Neuropathy in SSc: A Frequent and Disabling Manifestation in SSc, and a Potential Surrogate Marker for Autonomic Neuropathy

10:30AM-12:30PM: Abstract Number: 2451

Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients

10:30AM-12:30PM: Abstract Number: 2470

Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases

10:30AM-12:30PM: Abstract Number: 2477

Quantifying Tissue Microstructural Changes in Scleroderma Skin Using a Novel, Point-of-care, High-frequency-ultrasound Instrument

10:30AM-12:30PM: Abstract Number: 2466

Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 2458

Risk Factors for Progression of Interstitial Lung Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2460

Severe Gastrointestinal Involvement in Systemic Sclerosis: A New “Transversal” Subset of Disease to Be Prioritised for Intervention Trials

10:30AM-12:30PM: Abstract Number: 2465

Subclinical Loss of Lung Volumes in Very Early SSc: Evidence from Two Independent Cohorts in EUSTAR

10:30AM-12:30PM: Abstract Number: 2443

The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort

10:30AM-12:30PM: Abstract Number: 2475

The Critical Role of Annual HRCT in Identifying ILD Progression and Assessing Outcome in SSc

10:30AM-12:30PM: Abstract Number: 2476

The Impact of Systemic Sclerosis Manifestations on Survival and Humanistic Burden: A Targeted Literature Review

10:30AM-12:30PM: Abstract Number: 2464

Thymic Size Longitudinal Changes on Chest High-resolution Computed Tomography After Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 2459

Use of Nailfold Capillaroscopy as a Predictor of Cardiovascular Events and Mortality in Systemic Sclerosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].